| UniProt ID | NS1BP_HUMAN | |
|---|---|---|
| UniProt AC | Q9Y6Y0 | |
| Protein Name | Influenza virus NS1A-binding protein | |
| Gene Name | IVNS1ABP {ECO:0000312|HGNC:HGNC:16951} | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 642 | |
| Subcellular Localization | Cytoplasm . Cytoplasm, cytoskeleton . Nucleus, nucleoplasm . Associated with actin filaments (By similarity). Localization related to speckle domains which correspond to interchromatin granules and are enriched in factors involved in pre-mRNA splicin | |
| Protein Description | Involved in many cell functions, including pre-mRNA splicing, the aryl hydrocarbon receptor (AHR) pathway, F-actin organization and protein ubiquitination. Plays a role in the dynamic organization of the actin skeleton as a stabilizer of actin filaments by association with F-actin through Kelch repeats (By similarity). Protects cells from cell death induced by actin destabilization (By similarity). Functions as modifier of the AHR/Aryl hydrocarbon receptor pathway increasing the concentration of AHR available to activate transcription. [PubMed: 16582008 In addition, functions as a negative regulator of BCR(KLHL20) E3 ubiquitin ligase complex to prevent ubiquitin-mediated proteolysis of PML and DAPK1, two tumor suppressors] | |
| Protein Sequence | MIPNGYLMFEDENFIESSVAKLNALRKSGQFCDVRLQVCGHEMLAHRAVLACCSPYLFEIFNSDSDPHGISHVKFDDLNPEAVEVLLNYAYTAQLKADKELVKDVYSAAKKLKMDRVKQVCGDYLLSRMDVTSCISYRNFASCMGDSRLLNKVDAYIQEHLLQISEEEEFLKLPRLKLEVMLEDNVCLPSNGKLYTKVINWVQRSIWENGDSLEELMEEVQTLYYSADHKLLDGNLLDGQAEVFGSDDDHIQFVQKKPPRENGHKQISSSSTGCLSSPNATVQSPKHEWKIVASEKTSNNTYLCLAVLDGIFCVIFLHGRNSPQSSPTSTPKLSKSLSFEMQQDELIEKPMSPMQYARSGLGTAEMNGKLIAAGGYNREECLRTVECYNPHTDHWSFLAPMRTPRARFQMAVLMGQLYVVGGSNGHSDDLSCGEMYDSNIDDWIPVPELRTNRCNAGVCALNGKLYIVGGSDPYGQKGLKNCDVFDPVTKLWTSCAPLNIRRHQSAVCELGGYLYIIGGAESWNCLNTVERYNPENNTWTLIAPMNVARRGAGVAVLNGKLFVCGGFDGSHAISCVEMYDPTRNEWKMMGNMTSPRSNAGIATVGNTIYAVGGFDGNEFLNTVEVYNLESNEWSPYTKIFQF | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 10 | Ubiquitination | PNGYLMFEDENFIES CCCEEEECCCCHHHH | 50.91 | 22817900 | |
| 14 | Ubiquitination | LMFEDENFIESSVAK EEECCCCHHHHHHHH | 6.53 | 21890473 | |
| 21 | Ubiquitination | FIESSVAKLNALRKS HHHHHHHHHHHHHHC | 39.87 | 27667366 | |
| 27 | Ubiquitination | AKLNALRKSGQFCDV HHHHHHHHCCCCCCE | 60.84 | - | |
| 28 | Phosphorylation | KLNALRKSGQFCDVR HHHHHHHCCCCCCEE | 31.24 | 21815630 | |
| 54 | Phosphorylation | RAVLACCSPYLFEIF HHHHHHHCHHHHHHH | 19.23 | - | |
| 63 | Phosphorylation | YLFEIFNSDSDPHGI HHHHHHCCCCCCCCC | 27.95 | - | |
| 71 | Phosphorylation | DSDPHGISHVKFDDL CCCCCCCCCCEECCC | 27.16 | - | |
| 99 | Ubiquitination | TAQLKADKELVKDVY HHHHHCCHHHHHHHH | 58.78 | 22817900 | |
| 103 | Ubiquitination | KADKELVKDVYSAAK HCCHHHHHHHHHHHH | 54.85 | 22817900 | |
| 110 | Ubiquitination | KDVYSAAKKLKMDRV HHHHHHHHHCCHHHH | 59.35 | 27667366 | |
| 118 | Ubiquitination | KLKMDRVKQVCGDYL HCCHHHHHHHHHHHH | 37.60 | - | |
| 172 | Ubiquitination | SEEEEFLKLPRLKLE CCHHHHHCCCCCEEE | 62.86 | 29967540 | |
| 197 | Ubiquitination | SNGKLYTKVINWVQR CCCEEHHHHHHHHHH | 27.79 | - | |
| 246 | Phosphorylation | GQAEVFGSDDDHIQF CCEEECCCCCCCEEE | 26.80 | 25159151 | |
| 256 | Ubiquitination | DHIQFVQKKPPRENG CCEEEECCCCCCCCC | 63.04 | 29967540 | |
| 259 | Ubiquitination | QFVQKKPPRENGHKQ EEECCCCCCCCCCCC | 66.16 | 21890473 | |
| 262 | Ubiquitination | QKKPPRENGHKQISS CCCCCCCCCCCCCCC | 60.18 | 22817900 | |
| 265 | Ubiquitination | PPRENGHKQISSSST CCCCCCCCCCCCCCC | 51.21 | 29967540 | |
| 266 | Ubiquitination | PRENGHKQISSSSTG CCCCCCCCCCCCCCC | 34.81 | 21890473 | |
| 268 | Phosphorylation | ENGHKQISSSSTGCL CCCCCCCCCCCCCCC | 22.98 | 25159151 | |
| 269 | Phosphorylation | NGHKQISSSSTGCLS CCCCCCCCCCCCCCC | 29.91 | 25159151 | |
| 269 | Ubiquitination | NGHKQISSSSTGCLS CCCCCCCCCCCCCCC | 29.91 | 22817900 | |
| 270 | Phosphorylation | GHKQISSSSTGCLSS CCCCCCCCCCCCCCC | 25.73 | 25159151 | |
| 271 | Phosphorylation | HKQISSSSTGCLSSP CCCCCCCCCCCCCCC | 30.66 | 25159151 | |
| 272 | Phosphorylation | KQISSSSTGCLSSPN CCCCCCCCCCCCCCC | 33.58 | 25159151 | |
| 276 | Phosphorylation | SSSTGCLSSPNATVQ CCCCCCCCCCCCEEC | 48.07 | 25159151 | |
| 277 | Phosphorylation | SSTGCLSSPNATVQS CCCCCCCCCCCEECC | 14.82 | 25159151 | |
| 281 | Phosphorylation | CLSSPNATVQSPKHE CCCCCCCEECCCCCE | 26.22 | 20068231 | |
| 284 | Phosphorylation | SPNATVQSPKHEWKI CCCCEECCCCCEEEE | 31.42 | 20068231 | |
| 286 | Ubiquitination | NATVQSPKHEWKIVA CCEECCCCCEEEEEE | 60.44 | 29967540 | |
| 290 | Ubiquitination | QSPKHEWKIVASEKT CCCCCEEEEEEEEEC | 25.07 | 29967540 | |
| 322 | Phosphorylation | IFLHGRNSPQSSPTS EEECCCCCCCCCCCC | 23.97 | 29255136 | |
| 325 | Phosphorylation | HGRNSPQSSPTSTPK CCCCCCCCCCCCCCC | 41.49 | 23663014 | |
| 326 | Phosphorylation | GRNSPQSSPTSTPKL CCCCCCCCCCCCCCH | 27.27 | 16964243 | |
| 328 | Phosphorylation | NSPQSSPTSTPKLSK CCCCCCCCCCCCHHH | 47.37 | 21955146 | |
| 329 | Phosphorylation | SPQSSPTSTPKLSKS CCCCCCCCCCCHHHC | 46.20 | 23663014 | |
| 330 | Phosphorylation | PQSSPTSTPKLSKSL CCCCCCCCCCHHHCC | 27.24 | 21955146 | |
| 334 | Phosphorylation | PTSTPKLSKSLSFEM CCCCCCHHHCCCCEE | 26.73 | 29116813 | |
| 336 | Phosphorylation | STPKLSKSLSFEMQQ CCCCHHHCCCCEECH | 26.35 | 25159151 | |
| 338 | Phosphorylation | PKLSKSLSFEMQQDE CCHHHCCCCEECHHH | 26.67 | 25159151 | |
| 352 | Phosphorylation | ELIEKPMSPMQYARS HHHHCCCCHHHHHHC | 26.25 | 25159151 | |
| 356 | Phosphorylation | KPMSPMQYARSGLGT CCCCHHHHHHCCCCC | 9.57 | 23663014 | |
| 363 | Phosphorylation | YARSGLGTAEMNGKL HHHCCCCCHHHCCEE | 25.20 | - | |
| 369 | Ubiquitination | GTAEMNGKLIAAGGY CCHHHCCEEEEECCC | 31.54 | - | |
| 395 | Ubiquitination | YNPHTDHWSFLAPMR CCCCCCCCCHHCCCC | 8.12 | 21890473 | |
| 398 | Ubiquitination | HTDHWSFLAPMRTPR CCCCCCHHCCCCCHH | 4.34 | 22817900 | |
| 464 | Ubiquitination | GVCALNGKLYIVGGS CEEEECCEEEEEECC | 36.72 | - | |
| 471 | Phosphorylation | KLYIVGGSDPYGQKG EEEEEECCCCCCCCC | 29.50 | 28152594 | |
| 474 | Phosphorylation | IVGGSDPYGQKGLKN EEECCCCCCCCCCCC | 36.86 | 28152594 | |
| 477 | Ubiquitination | GSDPYGQKGLKNCDV CCCCCCCCCCCCCCC | 62.94 | 22817900 | |
| 480 | Ubiquitination | PYGQKGLKNCDVFDP CCCCCCCCCCCCCCC | 65.29 | 22817900 | |
| 484 | Ubiquitination | KGLKNCDVFDPVTKL CCCCCCCCCCCHHHH | 6.80 | 21890473 | |
| 487 | Ubiquitination | KNCDVFDPVTKLWTS CCCCCCCCHHHHHHH | 24.98 | 22817900 | |
| 490 | Ubiquitination | DVFDPVTKLWTSCAP CCCCCHHHHHHHCCC | 42.11 | - | |
| 493 | Phosphorylation | DPVTKLWTSCAPLNI CCHHHHHHHCCCCCC | 25.10 | 26657352 | |
| 494 | Phosphorylation | PVTKLWTSCAPLNIR CHHHHHHHCCCCCCH | 9.19 | 26657352 | |
| 638 | Sumoylation | NEWSPYTKIFQF--- CCCCCCEEEECC--- | 35.36 | - |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of NS1BP_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NS1BP_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NS1BP_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277 AND SER-338, ANDMASS SPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-338, AND MASSSPECTROMETRY. | |
| "Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-336 AND SER-338, ANDMASS SPECTROMETRY. | |
| "A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-277, AND MASSSPECTROMETRY. | |